author(s)
Deepak Sumbria and LD Singla

abstract
Cryptosporidiosis and toxoplasmosis are the two main emerging diseases of parasitic protozoan origin having a very wide range of hosts, including almost all mammals, birds, fish and reptiles which spread mainly via contaminated water and food.Large numbers of studies have described the parasitological, seroprevalence, molecular and geographic distribution of these organisms throughout the world. The importance and generation of great public health interest of these diseases is increasing day by day. As the chances of human-animal interaction get augmented in the changing scenario the probability of these economically important zoonotic infections also goes up. As at present no vaccine with 100% efficacy is available against these diseases, hence preventive and chemotherapeutic measures mainly rely on the effective use of various chemotherapeutic agents. Currently different drug for chemoprophylaxis and chemotherapy have been tried which include Nitazoxanide, Halofuginone, Paromomycin, Azithromycin, Rifaximin etc. against cryptosporidiosis. On the other hand for the preclusion of toxoplasmosis main drugs used include are Bisphosphonates: farnysyl diphosphate inhibitors, Bumped kinase inhibitors, Dihydrofolate reductase inhibitors, Endoplasmic reticulum-associated degradation inhibitors, Fatty acid synthesis inhibitors, Fluoroquinolone derivatives, Histone acetyl-transferase/histone deacetylase inhibitors, Macrolide derivatives, Peptide-conjugated phosphorodiamidate morpholino oligomers, 4-(1H)-quinolones and Thiosemicarbazones with capricious success rates. The main aim of this article is to discuss the current significance of available chemotherapeutic agents in relation to their effectiveness in order to cure or decrease the potential of economic losses caused these protozoan infections. Additionally historical background, pharmacokinetics, mode of action, various in-vitro and in-vivo trails aspects have also been discussed.